- Company
- Dispute over Eliquis patent will be closed in six years
- by Kim, Jin-Gu Apr 5, 2021 05:51am
- The six-year-old Eliquis (Apixaban) substance patent lawsuit will be closed next week in the Supreme Court. If the Supreme Court overturns the judgment of the first and second trials and takes the side of the original company, BMS, an all-round lawsuit for damages against related generic companies is expected and attracts attention. The r
- Company
- OB-GYNs fume over the price hike of HPV vaccines
- by Moon, sung-ho Apr 5, 2021 05:51am
- The medical community is in turmoil over the news that MSD Korea will raise the price of ‘Gardasil 9,’ its 9-valent HPV vaccine. Relevant doctors’ associations are determined to discuss countermeasures for the unilateral price increase carried out by the pharmaceutical company. The Korean company in charge of domestic sales of the vaccine
- Company
- Novartis' Xolair self-administration prescribed at GHs
- by Eo, Yun-Ho Apr 2, 2021 06:06am
- The self-administration formulation of the asthma treatment ‘Xolair’ can now be prescribed at general hospitals. According to industry sources, Novartis Korea’s Xolair (omalizumab) prefilled syringe 75mg solution has passed the review of drug committees (DCs) in 8 general hospitals nationwide, including the Seoul National University
- Company
- Aldactone, which was frequently sold out, is resupplied
- by Apr 2, 2021 06:05am
- Pfizer Korea's diuretic drug Aldactone, which was often sold out, is scheduled to resume supply. According to the distribution industry on the 27th, the supply of Aldactone (Spironolactone) 25mg is expected to resume from the 29th. It was earlier than the April 8th, the resupply date originally expected by the company. Aldactone is oft
- Company
- Only hope for pancreatic cancer Onivyde seeking for coverage
- by Eo, Yun-Ho Apr 1, 2021 06:08am
- The pancreatic cancer with highly unmet medical needs may welcome a newly listed drug. The pharmaceutical industry sources reported Servier Korea’s Onivyde (Irinotecan Hydrochloride) would be deliberated by the Health Insurance Review and Assessment Service (HIRA) Drug Reimbursement Evaluation Committee (DREC). Requested for the Nationa
- Company
- Equfina can be prescribed at general hospitals
- by Eo, Yun-Ho Mar 31, 2021 06:08am
- Equfina, a treatment for Parkinson's disease from Esai, can be prescribed in general hospitals. According to related industries, Equfina (Safinamide) has passed the drug committee (DC) of Seoul National University Hospital and Asan Medical Center among Big 5 medical institutions, and is undergoing landing procedures at major medical institu
- Company
- “EMA authorizes Rekirona, sales projected at KRW 1.2 tln”
- by Kim, Jin-Gu Mar 31, 2021 06:06am
- The financial experts project Celltrion's COVID-19 monoclonal antibody treatment Rekirona injection’s (regdanvimab) sales in Europe would hit 1.2 trillion won as the European Medicines Agency (EMA) has granted conditional approval on the treatment. Leveraged by the Rekirona sales in Europe, the experts also projected Celltrion’s annual
- Company
- Controversy over 7-day packaging Rx drugs
- by Nho, Byung Chul Mar 29, 2021 05:58am
- Due to the packaging unit different from the domestic prescription style, drug prescription and storage difficulties for pharmacists and patients in countries are increasing and improvement is required. According to the pharmacy, it is difficult to dispensing some high-frequency, long-term prescription drugs because the packaging unit is s
- Company
- Boehringer is interested in open innovation with Yuhan
- by Mar 29, 2021 05:58am
- Boehringer Ingelheim emphasized the importance of open innovation and announced that it has a long-term partnership with Yuhan. It also mentioned the possibility of further open innovation for R&D materials in Korea. In addition, they expressed their will to do their best in the development of COVID-19 treatment and anticancer drugs targeting
- Company
- Bonviva generics dodge a bullet from patent dispute
- by Kim, Jin-Gu Mar 26, 2021 05:38am
- The generic makers won the patent dispute over an antiarthritis Bonviva (ibandronate) and now they are finally free from the risk of sales ban and damage compensation. According to the pharmaceutical industry source on Mar. 23, the Intellectual Property Trial and Appeal Board issued a trial decision that the dosage regimen patent for Bon
